Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single Arm, Phase I Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare

NCT05580042 is registered in ClinicalTrials.gov with TWi Biotechnology, Inc. as lead sponsor.

NCT NCT05580042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05580042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single Arm, Phase I Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare
Lead sponsor
TWi Biotechnology, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 3, 2022
Completion date
November 15, 2023
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

granuloma annulare